Literature DB >> 34694362

mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells Persist at 6 Months and Recognize the Delta Variant.

Bezawit A Woldemeskel1, Caroline C Garliss1, Joel N Blankson1.   

Abstract

Little is known about the decay kinetics of coronavirus disease 2019 vaccine-elicited severe acute respiratory syndrome coronavirus 2-specific T cells. In this study we show a modest decline in the frequency of these T cells at 6 months and demonstrate robust expansion in response to antigen and recognition of spike peptides from the Delta variant.
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID; Delta variant; SARS-CoV-2; T cells; mRNA vaccines

Mesh：

Substances：

Year:  2022        PMID： 34694362     DOI： 10.1093/cid/ciab915

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


  14 in total

1.  Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.

Authors:  Bezawit A Woldemeskel; Andrew H Karaba; Caroline C Garliss; Evan J Beck; Tihitina Y Aytenfisu; Trevor S Johnston; Oliver Laeyendecker; Andrea L Cox; Joel N Blankson
Journal:  AIDS       Date:  2022-07-15       Impact factor: 4.632

2.  Potential Role of the Moderna COVID-19 Vaccine in Enoxaparin's Effects on Liver Functions.

Authors:  Omar Rafa; Iger Ostreni; Eric J Basile; Avneet Singh
Journal:  Cureus       Date:  2022-04-10

3.  SARS-CoV-2 vaccination diversifies the CD4+ spike-reactive T cell repertoire in patients with prior SARS-CoV-2 infection.

Authors:  Arbor G Dykema; Boyang Zhang; Bezawit A Woldemeskel; Caroline C Garliss; Rufiaat Rashid; Timothy Westlake; Li Zhang; Jiajia Zhang; Laurene S Cheung; Justina X Caushi; Drew M Pardoll; Andrea L Cox; Hongkai Ji; Kellie N Smith; Joel N Blankson
Journal:  EBioMedicine       Date:  2022-05-06       Impact factor: 11.205

4.  Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland.

Authors:  Piotr Rzymski; Monika Pazgan-Simon; Juliusz Kamerys; Anna Moniuszko-Malinowska; Katarzyna Sikorska; Joanna Wernik; Dorota Zarębska-Michaluk; Łukasz Supronowicz; Barbara Sobala-Szczygieł; Agata Skrzat-Klapaczyńska; Krzysztof Simon; Anna Piekarska; Piotr Czupryna; Małgorzata Pawłowska; Michał Brzdęk; Jerzy Jaroszewicz; Justyna Kowalska; Marcin Renke; Robert Flisiak
Journal:  Vaccines (Basel)       Date:  2022-04-04

5.  Broadly recognized, cross-reactive SARS-CoV-2 CD4 T cell epitopes are highly conserved across human coronaviruses and presented by common HLA alleles.

Authors:  Aniuska Becerra-Artiles; J Mauricio Calvo-Calle; Mary Dawn Co; Padma P Nanaware; John Cruz; Grant C Weaver; Liying Lu; Catherine Forconi; Robert W Finberg; Ann M Moormann; Lawrence J Stern
Journal:  Cell Rep       Date:  2022-05-27       Impact factor: 9.995

6.  Differential T-Cell Immunity to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in mRNA-1273- and BNT162b2-Vaccinated Individuals.

Authors:  Kathleen M E Gallagher; Mark B Leick; Rebecca C Larson; Trisha R Berger; Katelin Katsis; Jennifer Y Yam; Marcela V Maus
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

7.  Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data.

Authors:  Natalia A Díaz; Rosa de Miguel; Fernando Agüero; Omar Sued; José R Arribas; Juan Ambrosioni
Journal:  Infect Dis Ther       Date:  2021-10-28

8.  Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies.

Authors:  Laura Vitiello; Lucia Gatta; Sara Ilari; Stefano Bonassi; Mario Cristina; Filippo Ciatti; Massimo Fini; Stefania Proietti; Patrizia Russo; Carlo Tomino; Dolores Limongi
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

9.  Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?

Authors:  Roberto Stellini; Renzo Gianello; Walter Gomarasca
Journal:  Infection       Date:  2022-04-07       Impact factor: 3.553

Review 10.  COVID-19 vaccinations: The unknowns, challenges, and hopes.

Authors:  Kawthar Mohamed; Piotr Rzymski; Md Shahidul Islam; Rangarirai Makuku; Ayesha Mushtaq; Amjad Khan; Mariya Ivanovska; Sara A Makka; Fareeda Hashem; Leander Marquez; Orsolya Cseprekal; Igor Salerno Filgueiras; Dennyson Leandro M Fonseca; Essouma Mickael; Irene Ling; Amanuel Godana Arero; Sarah Cuschieri; Kseniia Minakova; Eduardo Rodríguez-Román; Sunny O Abarikwu; Attig-Bahar Faten; Giulia Grancini; Otavio Cabral-Marques; Nima Rezaei
Journal:  J Med Virol       Date:  2021-12-10       Impact factor: 20.693
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.